CoChat
Sign Up
Cited by 83Obsessive-Compulsive Spectrum DisordersPsychoanalysis and Psychopathology ResearchAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder

Open access
Marinova, Zoya, Chuang, De-Maw, Fineberg, Naomi·2017·Current Neuropharmacology
DOI 10.2174/1570159x15666170320104237PMC PMC5652017
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: Obsessive-compulsive disorder (OCD) is a mental disease commonly associated with severe distress and impairment of social functioning. Serotonin reuptake inhibitors and/or cognitive behavioural therapy are the therapy of choice, however up to 40% of patients do not respond to treatment. Glutamatergic signalling has also been implicated in OCD. The aim of the current study was to review the clinical evidence for therapeutic utility of glutamate-modulating drugs as an augmentation or monotherapy in OCD patients. METHODS: We conducted a search of the MEDLINE database for clinical studies evaluating the effect of glutamate-modulating drugs in OCD. RESULTS: Memantine is the compound most consistently showing a positive effect as an augmentation therapy in OCD. Anti-convulsant drugs (lamotrigine, topiramate) and riluzole may also provide therapeutic benefit to some OCD patients. Finally, ketamine may be of interest due to its potential for a rapid onset of action. CONCLUSION: Further randomized placebo-controlled trials in larger study populations are necessary in order to draw definitive conclusions on the utility of glutamate-modulating drugs in OCD. Furthermore, genetic and epigenetic factors, clinical symptoms and subtypes predicting treatment response to glutamate-modulating drugs need to be investigated systematically.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x15666170320104237

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 154 · Cited by 83

Research works printed but not linked: 120

  1. [1]Fineberg N.A. Hengartner M.P. Bergbaum C.E. Gale T.M. Gamma A. Ajdacic-Gross V. Rössler W. Angst J. A prospective population-based cohort study of the prevalence, incidence and impact of obsessive-compulsive symptomatology. Int. J. Psychiatry Clin. Pract. 2013 17 3 170 178 [http://dx.doi.org/10.3109/ 13651501.2012.755206]. [PMID: 23205952]. 23205952
  2. [2]Kalra S.K. Swedo S.E. Children with obsessive-compulsive disorder: are they just “little adults”? J. Clin. Invest. 2009 119 4 737 746 [http://dx.doi.org/10.1172/JCI37563]. [PMID: 19339765]. 19339765 PMC2662563 · DOI · Paper page
  3. [4]Timpano K.R. Rubenstein L.M. Murphy D.L. Phenomenological features and clinical impact of affective disorders in OCD: a focus on the bipolar disorder and OCD connection. Depress. Anxiety 2012 29 3 226 233 [http://dx.doi.org/10.1002/da.20908]. [PMID: 22109969]. 22109969 PMC3322278 · DOI
  4. [5]Saxena S. Rauch S.L. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr. Clin. North Am. 2000 23 3 563 586 [http://dx.doi.org/10.1016/S0193-953X(05)70181-7]. [PMID: 10986728]. 10986728 · DOI · Paper page
  5. [6]Burguière E. Monteiro P. Mallet L. Feng G. Graybiel A.M. Striatal circuits, habits, and implications for obsessive-compulsive disorder. Curr. Opin. Neurobiol. 2015 30 59 65 [http://dx.doi. org/10.1016/j.conb.2014.08.008]. [PMID: 25241072]. 25241072 PMC4293232 · DOI · Paper page
  6. [8]Radua J. Mataix-Cols D. Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. Br. J. Psychiatry 2009 195 5 393 402 [http://dx.doi.org/10.1192/bjp.bp.108. 055046]. [PMID: 19880927]. 19880927 · DOI
  7. [9]Whiteside S.P. Port J.D. Abramowitz J.S. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res. 2004 132 1 69 79 [http://dx.doi.org/10.1016/ j.pscychresns.2004.07.001]. [PMID: 15546704]. 15546704
  8. [11]Ting J.T. Feng G. Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics. Curr. Opin. Neurobiol. 2011 21 6 842 848 [http://dx.doi. org/10.1016/j.conb.2011.04.010]. [PMID: 21605970]. 21605970 PMC3192923 · DOI · Paper page
  9. [12]Ting J.T. Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr. Chem. Genomics 2008 2 62 75 [http://dx.doi.org/10.2174/1875397300802010062]. [PMID: 19768139]. 19768139 PMC2746669 · DOI
  10. [15]Rosenberg D.R. Mirza Y. Russell A. Tang J. Smith J.M. Banerjee S.P. Bhandari R. Rose M. Ivey J. Boyd C. Moore G.J. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J. Am. Acad. Child Adolesc. Psychiatry 2004 43 9 1146 1153 [http://dx.doi.org/10.1097/01.chi.0000132812.44664.2d]. [PMID: 15322418]. 15322418 · DOI · Paper page
  11. [17]Shin D.J. Jung W.H. He Y. Wang J. Shim G. Byun M.S. Jang J.H. Kim S.N. Lee T.Y. Park H.Y. Kwon J.S. The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol. Psychiatry 2014 75 8 606 614 [http://dx.doi.org/10.1016/j.biopsych.2013.09.002]. [PMID: 24099506]. 24099506 · DOI · Paper page
  12. [19]Mattheisen M. Samuels J.F. Wang Y. Greenberg B.D. Fyer A.J. McCracken J.T. Geller D.A. Murphy D.L. Knowles J.A. Grados M.A. Riddle M.A. Rasmussen S.A. McLaughlin N.C. Nurmi E.L. Askland K.D. Qin H.D. Cullen B.A. Piacentini J. Pauls D.L. Bienvenu O.J. Stewart S.E. Liang K.Y. Goes F.S. Maher B. Pulver A.E. Shugart Y.Y. Valle D. Lange C. Nestadt G. Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS. Mol. Psychiatry 2015 20 3 337 344 [http://dx.doi.org/10.1038/mp.2014.43]. [PMID: 24821223]. 24821223 PMC4231023 · DOI · Paper page
  13. [20]Stewart S.E. Yu D. Scharf J.M. Neale B.M. Fagerness J.A. Mathews C.A. Arnold P.D. Evans P.D. Gamazon E.R. Davis L.K. Osiecki L. McGrath L. Haddad S. Crane J. Hezel D. Illman C. Mayerfeld C. Konkashbaev A. Liu C. Pluzhnikov A. Tikhomirov A. Edlund C.K. Rauch S.L. Moessner R. Falkai P. Maier W. Ruhrmann S. Grabe H.J. Lennertz L. Wagner M. Bellodi L. Cavallini M.C. Richter M.A. Cook E.H. Jr Kennedy J.L. Rosenberg D. Stein D.J. Hemmings S.M. Lochner C. Azzam A. Chavira D.A. Fournier E. Garrido H. Sheppard B. Umaña P. Murphy D.L. Wendland J.R. Veenstra-Vander W.J. Denys D. Blom R. Deforce D. Van Nieuwerburgh F. Westenberg H.G. Walitza S. Egberts K. Renner T. Miguel E.C. Cappi C. Hounie A.G. Conceição do Rosário M. Sampaio A.S. Vallada H. Nicolini H. Lanzagorta N. Camarena B. Delorme R. Leboyer M. Pato C.N. Pato M.T. Voyiaziakis E. Heutink P. Cath D.C. Posthuma D. Smit J.H. Samuels J. Bienvenu O.J. Cullen B. Fyer A.J. Grados M.A. Greenberg B.D. McCracken J.T. Riddle M.A. Wang Y. Coric V. Leckman J.F. Bloch M. Pittenger C. Eapen V. Black D.W. Ophoff R.A. Strengman E. Cusi D. Turiel M. Frau F. Macciardi F. Gibbs J.R. Cookson M.R. Singleton A. Hardy J. Crenshaw A.T. Parkin M.A. Mirel D.B. Conti D.V. Purcell S. Nestadt G. Hanna G.L. Jenike M.A. Knowles J.A. Cox N. Pauls D.L. Genome-wide association study of obsessive-compulsive disorder. Mol. Psychiatry 2013 18 7 788 798 [Erratum in: Mol Psychiatry 18:843. Davis, LK]. [added]. [http://dx.doi.org/10.1038/mp.2012.85]. [PMID: 22889921]. 22889921 PMC4218751 · DOI · Paper page
  14. [21]Qin H. Samuels J.F. Wang Y. Zhu Y. Grados M.A. Riddle M.A. Greenberg B.D. Knowles J.A. Fyer A.J. McCracken J.T. Murphy D.L. Rasmussen S.A. Cullen B.A. Piacentini J. Geller D. Stewart S.E. Pauls D. Bienvenu O.J. Goes F.S. Maher B. Pulver A.E. Valle D. Lange C. Mattheisen M. McLaughlin N.C. Liang K.Y. Nurmi E.L. Askland K.D. Nestadt G. Shugart Y.Y. Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol. Psychiatry 2016 21 2 270 276 [http://dx.doi.org/10.1038/mp.2015. 32]. [PMID: 25824302]. 25824302 PMC5027902 · DOI
  15. [22]Goodman W.K. McDougle C.J. Price L.H. Riddle M.A. Pauls D.L. Leckman J.F. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J. Clin. Psychiatry 1990 51 Suppl. 36 43 [PMID: 2199433]. 2199433
  16. [23]Denys D. Zohar J. Westenberg H.G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J. Clin. Psychiatry 2004 65 Suppl. 14 11 17 [PMID: 15554783]. 15554783
  17. [24]Teixeira A.L. Rodrigues D.H. Marques A.H. Miguel E.C. Fontenelle L.F. Searching for the immune basis of obsessive-compulsive disorder. Neuroimmunomodulation 2014 21 2-3 152 158 [http://dx.doi.org/10.1159/000356554]. [PMID: 24557049]. 24557049 · DOI
  18. [25]Pearlman D.M. Vora H.S. Marquis B.G. Najjar S. Dudley L.A. Anti-basal ganglia antibodies in primary obsessive-compulsive disorder: systematic review and meta-analysis. Br. J. Psychiatry 2014 205 1 8 16 [http://dx.doi.org/10.1192/bjp.bp. 113.137018]. [PMID: 24986387]. 24986387 · DOI
  19. [26]McDougle C.J. Barr L.C. Goodman W.K. Price L.H. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 1999 24 1 1 24 [http://dx.doi.org/10.1016/S0306-4530(98)00046-8]. [PMID: 10098217]. 10098217 · DOI
  20. [27]Williams K.E. Koran L.M. Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. J. Clin. Psychiatry 1997 58 7 330 334 [http://dx.doi.org/10.4088/JCP. v58n0709]. [PMID: 9269260]. 9269260 · DOI
  21. [28]Alonso P. Gratacòs M. Segalàs C. Escaramís G. Real E. Bayés M. Labad J. Pertusa A. Vallejo J. Estivill X. Menchón J.M. Variants in estrogen receptor alpha gene are associated with phenotypical expression of obsessive-compulsive disorder. Psychoneuroendocrinology 2011 36 4 473 483 [http://dx. doi.org/10.1016/j.psyneuen.2010.07.022]. [PMID: 20850223]. 20850223 · DOI
  22. [29]Marazziti D. Masala I. Rossi A. Hollander E. Presta S. Giannaccini G. Mazzoni M.R. Dell’Osso L. Lucacchini A. Cassano G.B. Increased inhibitory activity of protein kinase C on the serotonin transporter in OCD. Neuropsychobiology 2000 41 4 171 177 [http://dx.doi.org/10.1159/000026656]. [PMID: 10828725]. 10828725 · DOI
  23. [30]Perez J. Tardito D. Ravizza L. Racagni G. Mori S. Maina G. Altered cAMP-dependent protein kinase A in platelets of patients with obsessive-compulsive disorder. Am. J. Psychiatry 2000 157 2 284 286 [http://dx.doi.org/10.1176/appi.ajp.157.2.284]. [PMID: 10671404]. 10671404 · DOI
  24. [31]Harvey B.H. Scheepers A. Brand L. Stein D.J. Chronic inositol increases striatal D(2) receptors but does not modify dexamphetamine-induced motor behavior. Relevance to obsessive-compulsive disorder. Pharmacol. Biochem. Behav. 2001 68 2 245 253 [http://dx.doi.org/10.1016/S0091-3057(00)00459-7]. [PMID: 11267629]. 11267629 · DOI
  25. [32]Wu K. Hanna G.L. Rosenberg D.R. Arnold P.D. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol. Biochem. Behav. 2012 100 4 726 735 [http://dx.doi.org/10.1016/j.pbb.2011.10.007]. [PMID: 22024159]. 22024159 PMC3437220 · DOI · Paper page
  26. [34]Sanacora G. Zarate C.A. Krystal J.H. Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008 7 5 426 437 [http://dx.doi.org/10.1038/nrd2462]. [PMID: 18425072]. 18425072 PMC2715836 · DOI · Paper page
  27. [35]Siegel S. Sanacora G. The roles of glutamate receptors across major neurological and psychiatric disorders. Pharmacol. Biochem. Behav. 2012 100 4 653 655 [http://dx.doi.org/10.1016/j.pbb. 2011.11.002]. [PMID: 22108650]. 22108650 · DOI
  28. [36]Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry. 2004 9 11 984 997 [http://dx.doi.org/10.1038/sj.mp.4001551] [PMID: 15278097]. 15278097 · DOI
  29. [37]Blackshaw L.A. Page A.J. Young R.L. Metabotropic glutamate receptors as novel therapeutic targets on visceral sensory pathways. Front. Neurosci. 2011 5 40 [http://dx.doi.org/10.3389/fnins. 2011.00040]. [PMID: 21472028]. 21472028 PMC3066463 · DOI
  30. [39]Wang L.P. Li F. Wang D. Xie K. Wang D. Shen X. Tsien J.Z. NMDA receptors in dopaminergic neurons are crucial for habit learning. Neuron 2011 72 6 1055 1066 [http://dx.doi.org/10. 1016/j.neuron.2011.10.019]. [PMID: 22196339]. 22196339 PMC3246213
  31. [41]Yuen E.Y. Jiang Q. Chen P. Feng J. Yan Z. Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex. J. Biol. Chem. 2008 283 25 17194 17204 [http://dx.doi.org/10.1074/jbc.M801713200]. [PMID: 18442977]. 18442977 PMC2427346 · DOI · Paper page
  32. [42]Delille H.K. Mezler M. Marek G.J. The two faces of the pharmacological interaction of mGlu2 and 5-HT2A - relevance of receptor heterocomplexes and interaction through functional brain pathways. Neuropharmacology 2013 70 296 305 [http://dx.doi.org/10.1016/j.neuropharm.2013.02.005]. [PMID: 23466331]. 23466331 · DOI
  33. [43]Shigeri Y. Seal R.P. Shimamoto K. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res. Brain Res. Rev. 2004 45 3 250 265 [http://dx.doi.org/10.1016/ j.brainresrev.2004.04.004]. [PMID: 15210307]. 15210307
  34. [44]Daikhin Y. Yudkoff M. Compartmentation of brain glutamate metabolism in neurons and glia. J. Nutr 2000 130 4S Suppl 1026S 1031S. 10736375
  35. [45]Soria F.N. Pérez-Samartín A. Martin A. Gona K.B. Llop J. Szczupak B. Chara J.C. Matute C. Domercq M. Extrasynaptic glutamate release through cystine/glutamate antiporter contributes to ischemic damage. J. Clin. Invest. 2014 124 8 3645 3655 [http://dx.doi.org/10.1172/JCI71886]. [PMID: 25036707]. 25036707 PMC4109556 · DOI
  36. [46]Chakrabarty K. Bhattacharyya S. Christopher R. Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005 30 9 1735 1740 [http://dx.doi.org/10.1038/sj.npp.1300733]. [PMID: 15841109]. 15841109 · DOI · Paper page
  37. [49]Arnold P.D. Sicard T. Burroughs E. Richter M.A. Kennedy J.L. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch. Gen. Psychiatry 2006 63 7 769 776 [http://dx.doi.org/10.1001/archpsyc.63.7.769]. [PMID: 16818866]. 16818866 · DOI · Paper page
  38. [51]Hanna G.L. Veenstra-VanderWeele J. Cox N.J. Boehnke M. Himle J.A. Curtis G.C. Leventhal B.L. Cook E.H. Jr Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. Am. J. Med. Genet. 2002 114 5 541 552 [http://dx.doi.org/10.1002/ajmg.10519]. [PMID: 12116192]. 12116192 · DOI
  39. [52]Egashira N. Okuno R. Harada S. Matsushita M. Mishima K. Iwasaki K. Nishimura R. Oishi R. Fujiwara M. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur. J. Pharmacol. 2008 586 1-3 164 170 [http://dx.doi.org/10.1016/j.ejphar.2008.01.035]. [PMID: 18423440]. 18423440 · DOI
  40. [53]Wald R. Dodman N. Shuster L. The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder. Exp. Clin. Psychopharmacol. 2009 17 3 191 197 [http://dx.doi.org/10.1037/a0016402]. [PMID: 19586234]. 19586234 · DOI
  41. [57]Franklin M.E. Foa E.B. Treatment of obsessive compulsive disorder. Annu. Rev. Clin. Psychol. 2011 7 229 243 [http://dx.doi.org/10.1146/annurev-clinpsy-032210-104533]. [PMID: 21443448]. 21443448 · DOI
  42. [58]Bridge J.A. Iyengar S. Salary C.B. Barbe R.P. Birmaher B. Pincus H.A. Ren L. Brent D.A. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007 297 15 1683 1696 [http://dx.doi.org/10.1001/jama. 297.15.1683]. [PMID: 17440145]. 17440145 · DOI
  43. [59]McDougle C.J. Goodman W.K. Leckman J.F. Lee N.C. Heninger G.R. Price L.H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry 1994 51 4 302 308 [http://dx.doi.org/10.1001/archpsyc. 1994.03950040046006]. [PMID: 8161290]. 8161290 · DOI
  44. [60]Fineberg N.A. Gale T.M. Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. Focus 2007 5 354 360 [http://dx.doi.org/10.1176/foc.5.3.foc354]. 16204331 · DOI
  45. [61]Niciu M.J. Henter I.D. Luckenbaugh D.A. Zarate C.A. Jr Charney D.S. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu. Rev. Pharmacol. Toxicol. 2014 54 119 139 [http://dx.doi.org/10.1146/annurev-pharmtox-011613-135950]. [PMID: 24392693]. 24392693 PMC4089991 · DOI
  46. [62]Pittenger C. Krystal J.H. Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J. Clin. Psychiatry 2005 66 11 1492 1493 [http://dx.doi.org/10. 4088/JCP.v66n1121d]. [PMID: 16420092]. 16420092
  47. [64]Murphy D.L. Moya P.R. Fox M.A. Rubenstein L.M. Wendland J.R. Timpano K.R. Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013 368 1615 20120435 [http://dx.doi.org/10.1098/rstb.2012. 0435]. [PMID: 23440468]. 23440468 PMC3638387 · DOI
  48. [65]Angst J. Gamma A. Endrass J. Hantouche E. Goodwin R. Ajdacic V. Eich D. Rössler W. Obsessive-compulsive syndromes and disorders: significance of comorbidity with bipolar and anxiety syndromes. Eur. Arch. Psychiatry Clin. Neurosci. 2005 255 1 65 71 [http://dx.doi.org/10.1007/s00406-005-0576-8]. [PMID: 15711895]. 15711895 · DOI
  49. [66]Wang S.J. Wang K.Y. Wang W.C. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004 125 1 191 201 [http://dx.doi.org/10.1016/j.neuroscience.2004.01.019]. [PMID: 15051158]. 15051158 · DOI
  50. [67]Frizzo M.E. Dall’Onder L.P. Dalcin K.B. Souza D.O. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell. Mol. Neurobiol. 2004 24 1 123 128 [http://dx.doi.org/10.1023/ B:CEMN.0000012717.37839.07]. [PMID: 15049516]. 15049516 PMC11529915
  51. [68]Grant P. Song J.Y. Swedo S.E. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2010 20 4 309 315 [http://dx. doi.org/10.1089/cap.2010.0009]. [PMID: 20807069]. 20807069 PMC2958461 · DOI · Paper page
  52. [69]Grant P.J. Joseph L.A. Farmer C.A. Luckenbaugh D.A. Lougee L.C. Zarate C.A. Jr Swedo S.E. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology 2014 39 6 1453 1459 [http://dx.doi.org/10.1038/npp.2013.343]. [PMID: 24356715]. 24356715 PMC3988548 · DOI
  53. [70]Coric V. Milanovic S. Wasylink S. Patel P. Malison R. Krystal J.H. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl.) 2003 167 2 219 220 [http://dx.doi.org/10.1007/s00213-003-1396-z]. [PMID: 12658528]. 12658528 · DOI
  54. [73]Pittenger C. Kelmendi B. Wasylink S. Bloch M.H. Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J. Clin. Psychopharmacol. 2008 28 3 363 367 [http://dx. doi.org/10.1097/JCP.0b013e3181727548]. [PMID: 18480706]. 18480706 · DOI
  55. [75]Emamzadehfard S. Kamaloo A. Paydary K. Ahmadipour A. Zeinoddini A. Ghaleiha A. Mohammadinejad P. Zeinoddini A. Akhondzadeh S. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study. Psychiatry Clin. Neurosci. 2016 70 8 332 341 [http://dx.doi.org/10.1111/pcn.12394]. [PMID: 27106362]. 27106362 · DOI
  56. [76]Kavirajan H. Memantine: a comprehensive review of safety and efficacy. Expert Opin. Drug Saf. 2009 8 1 89 109 [http://dx.doi.org/10.1517/14740330802528420]. [PMID: 19236221]. 19236221 · DOI
  57. [77]Poyurovsky M. Weizman R. Weizman A. Koran L. Memantine for treatment-resistant OCD. Am. J. Psychiatry 2005 162 11 2191 2192 [http://dx.doi.org/10.1176/appi.ajp.162.11.2191-a]. [PMID: 16263867]. 16263867 · DOI
  58. [78]Pasquini M. Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006 30 6 1173 1175 [http://dx.doi.org/10. 1016/j.pnpbp.2006.04.013]. [PMID: 16730870]. 16730870
  59. [80]Pekrul S.R. Fitzgerald K.D. Memantine augmentation in a down’s syndrome adolescent with treatment-resistant obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2015 25 7 593 595 [http://dx.doi.org/10.1089/cap.2015.0073]. [PMID: 26258664]. 26258664 · DOI
  60. [81]Aboujaoude E. Barry J.J. Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J. Clin. Psychopharmacol. 2009 29 1 51 55 [http://dx.doi.org/10.1097/JCP.0b013e318192e9a4]. [PMID: 19142108]. 19142108 · DOI
  61. [82]Feusner J.D. Kerwin L. Saxena S. Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol. Bull. 2009 42 1 81 93 [PMID: 19204653]. 19204653
  62. [83]Bakhla A.K. Verma V. Soren S. Sarkhel S. Chaudhury S. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. Ind. Psychiatry J. 2013 22 2 149 152 [http://dx.doi.org/10.4103/0972-6748.132930]. [PMID: 25013317]. 25013317 PMC4085808 · DOI
  63. [85]Haghighi M. Jahangard L. Mohammad-Beigi H. Bajoghli H. Hafezian H. Rahimi A. Afshar H. Holsboer-Trachsler E. Brand S. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl.) 2013 228 4 633 640 [http://dx. doi.org/10.1007/s00213-013-3067-z]. [PMID: 23525525]. 23525525 · DOI
  64. [86]Stewart S.E. Jenike E.A. Hezel D.M. Stack D.E. Dodman N.H. Shuster L. Jenike M.A. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J. Clin. Psychopharmacol. 2010 30 1 34 39 [http://dx.doi.org/10.1097/ JCP.0b013e3181c856de]. [PMID: 20075645]. 20075645
  65. [88]Rodriguez C.I. Kegeles L.S. Levinson A. Feng T. Marcus S.M. Vermes D. Flood P. Simpson H.B. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 2013 38 12 2475 2483 [http://dx.doi.org/10.1038/npp.2013.150]. [PMID: 23783065]. 23783065 PMC3799067 · DOI · Paper page
  66. [89]Bloch M.H. Wasylink S. Landeros-Weisenberger A. Panza K.E. Billingslea E. Leckman J.F. Krystal J.H. Bhagwagar Z. Sanacora G. Pittenger C. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol. Psychiatry 2012 72 11 964 970 [http://dx.doi.org/10.1016/j.biopsych.2012.05.028]. [PMID: 22784486]. 22784486 PMC3667652 · DOI · Paper page
  67. [90]Niciu M.J. Grunschel B.D. Corlett P.R. Pittenger C. Bloch M.H. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J. Psychopharmacol. (Oxford) 2013 27 7 651 654 [http://dx.doi.org/10.1177/0269881113486718]. [PMID: 23676198]. 23676198 · DOI
  68. [91]Rodriguez C.I. Levinson A. Zwerling J. Vermes D. Simpson H.B. Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion. J. Clin. Psychiatry 2016 77 5 688 689 [http://dx.doi.org/10.4088/ JCP.15l10318]. [PMID: 27249077]. 27249077 PMC5544938
  69. [92]Rodriguez C.I. Wheaton M. Zwerling J. Steinman S.A. Sonnenfeld D. Galfalvy H. Simpson H.B. Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial. J. Clin. Psychiatry 2016 77 3 408 409 [http://dx.doi.org/10.4088/JCP.15l10138]. [PMID: 27046314]. 27046314 PMC5544939 · DOI
  70. [93]Scheuing L. Chiu C.T. Liao H.M. Chuang D.M. Antidepressant mechanism of ketamine: perspective from preclinical studies. Front. Neurosci. 2015 9 249 [http://dx.doi.org/10.3389/fnins. 2015.00249]. [PMID: 26257598]. 26257598 PMC4508505 · DOI
  71. [94]Chiu C.T. Scheuing L. Liu G. Liao H.M. Linares G.R. Lin D. Chuang D.M. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int. J. Neuropsychopharmacol. 2014 18 6 pyu102 [PMID: 25548109]. 25548109 PMC4438544
  72. [95]Chiu C.T. Chuang D.M. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol. Ther. 2010 128 2 281 304 [http://dx.doi.org/10. 1016/j.pharmthera.2010.07.006]. [PMID: 20705090]. 20705090 PMC3167234
  73. [97]Cleveland W.L. DeLaPaz R.L. Fawwaz R.A. Challop R.S. High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period. Neural Plast 2009 768398. [http://dx.doi.org/10.1155/2009/768398] [PMID: 20182547]. PMC2825652 20182547 · DOI
  74. [98]Tsai G.E. Lin P.Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 2010 16 5 522 537 [http://dx.doi.org/10.2174/138161210790361452]. [PMID: 19909229]. 19909229 · DOI
  75. [99]Wu P.L. Tang H.S. Lane H.Y. Tsai C.A. Tsai G.E. Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J. Clin. Psychopharmacol. 2011 31 3 369 374 [http://dx.doi.org/10.1097/JCP.0b013e3182189878]. [PMID: 21508860]. 21508860 · DOI
  76. [100]Rubio G. Jiménez-Arriero M.A. Martínez-Gras I. Manzanares J. Palomo T. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J. Clin. Psychopharmacol. 2006 26 3 341 344 [http://dx.doi.org/10.1097/01.jcp.0000220524.44905.9f]. [PMID: 16702907]. 16702907 · DOI
  77. [101]Van Ameringen M. Mancini C. Patterson B. Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress. Anxiety 2006 23 1 1 5 [http://dx.doi.org/10.1002/da.20118]. [PMID: 16178009]. 16178009 · DOI
  78. [102]Hollander E. Dell’Osso B. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 2006 21 3 189 191 [http://dx.doi.org/10.1097/ 01.yic.0000199453.54799.cc]. [PMID: 16528143]. 16528143
  79. [103]Vinkers D.J. van der Wee N.J. Tijdschr. Psychiatr. 2008 50 11 747 750 [Topiramate augmentation in treatment-resistant obsessive-compulsive disorder]. [PMID: 18991236]. 18991236
  80. [104]Ozkara C. Ozmen M. Erdogan A. Yalug I. Topiramate related obsessive-compulsive disorder. Eur. Psychiatry 2005 20 1 78 79 [http://dx.doi.org/10.1016/j.eurpsy.2004.09.015]. [PMID: 15642451]. 15642451 · DOI
  81. [105]Thuile J. Even C. Guelfi J.D. Topiramate may induce obsessive-compulsive disorder. Psychiatry Clin. Neurosci. 2006 60 3 394 [http://dx.doi.org/10.1111/j.1440-1819.2006.01520.x]. [PMID: 16732760]. 16732760 · DOI
  82. [106]Mowla A. Khajeian A.M. Sahraian A. Chohedri A.H. Kashkoli F. Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectr. 2010 15 11 613 617 [http://dx.doi.org/10.1017/S1092852912000065]. [PMID: 24726048]. 24726048 · DOI
  83. [107]Berlin H.A. Koran L.M. Jenike M.A. Shapira N.A. Chaplin W. Pallanti S. Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry 2011 72 5 716 721 [http://dx.doi.org/10.4088/JCP.09m05266gre]. [PMID: 20816027]. 20816027 · DOI
  84. [108]Afshar H. Akuchekian S. Mahaky B. Zarean E. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J. Res. Med. Sci. 2014 19 10 976 981 [PMID: 25538783]. 25538783 PMC4274576
  85. [109]Leng Y. Fessler E.B. Chuang D.M. Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: roles of chromatin remodelling and Bcl-2 induction. Int. J. Neuropsychopharmacol. 2013 16 3 607 620 [http://dx.doi.org/10. 1017/S1461145712000429]. [PMID: 22564541]. 22564541 PMC6324934
  86. [110]Arrojo-Romero M. Tajes Alonso M. de Leon J. Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disor-der. 2013 PMC3725903 23936714
  87. [111]Uzun O. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. J. Psychopharmacol. (Oxford) 2010 24 3 425 427 [http://dx.doi.org/10. 1177/0269881108098809]. [PMID: 19010977]. 19010977
  88. [112]Naguy A. Alamiri B. Al-Khadhari S. Francis K. Lamotrigine augmentation in treatment-resistant pediatric obsessive-compulsive disorder with a 16 month follow-up. J. Child Adolesc. Psychopharmacol. 2016 26 8 769 772 [http://dx.doi.org/10.1089/ cap.2015.0083]. [PMID: 26465832]. 26465832
  89. [113]Hussain A. Dar M.A. Wani R.A. Shah M.S. Jan M.M. Malik Y.A. Chandel R.K. Margoob M.A. Role of lamotrigine augmentation in treatment-resistant obsessive compulsive disorder: a retrospective case review from South Asia. Indian J. Psychol. Med. 2015 37 2 154 158 [http://dx.doi.org/10.4103/0253-7176. 155613]. [PMID: 25969599]. 25969599 PMC4418246 · DOI
  90. [114]Kumar T.C. Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust. N. Z. J. Psychiatry 2000 34 3 527 528 [http://dx.doi.org/10.1080/ j.1440-1614.2000.0751c.x]. [PMID: 10881981]. 10881981
  91. [115]Bruno A. Micò U. Pandolfo G. Mallamace D. Abenavoli E. Di Nardo F. D’Arrigo C. Spina E. Zoccali R.A. Muscatello M.R. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J. Psychopharmacol. (Oxford) 2012 26 11 1456 1462 [http://dx.doi.org/10.1177/0269881111431751]. [PMID: 22351381]. 22351381 · DOI · Paper page
  92. [116]Khalkhali M. Aram S. Zarrabi H. Kafie M. Heidarzadeh A. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran. J. Psychiatry 2016 11 2 104 114 [PMID: 27437007]. 27437007 PMC4947218
  93. [117]Poyurovsky M. Glick I. Koran L.M. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J. Psychopharmacol. (Oxford) 2010 24 6 861 866 [http://dx.doi.org/10.1177/0269881108099215]. [PMID: 19074541]. 19074541 · DOI
  94. [118]Kemp D.E. Gilmer W.S. Fleck J. Dago P.L. An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder. CNS Spectr. 2007 12 2 106 111 [http://dx.doi.org/10.1017/S1092852900020617]. [PMID: 17277710]. 17277710 · DOI
  95. [119]Kuloglu M. Caykoylu A. Ekinci O. Yilmaz E. Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: a case report. J. Psychopharmacol. (Oxford) 2009 23 8 1001 1003 [http://dx.doi.org/10.1177/0269881108095082]. [PMID: 18719043]. 18719043 · DOI
  96. [120]Sansone R.A. Sansone L.A. Getting a Knack for NAC: N-Acetyl-Cysteine. Innov. Clin. Neurosci. 2011 8 1 10 14 [PMID: 21311702]. PMC3036554 21311702
  97. [121]Lafleur D.L. Pittenger C. Kelmendi B. Gardner T. Wasylink S. Malison R.T. Sanacora G. Krystal J.H. Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl.) 2006 184 2 254 256 [http://dx.doi.org/10.1007/s00213-005-0246-6]. [PMID: 16374600]. 16374600 · DOI
  98. [122]Afshar H. Roohafza H. Mohammad-Beigi H. Haghighi M. Jahangard L. Shokouh P. Sadeghi M. Hafezian H. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2012 32 6 797 803 [http://dx.doi.org/10.1097/JCP.0b013e318272677d]. [PMID: 23131885]. 23131885 · DOI
  99. [123]Sarris J. Oliver G. Camfield D.A. Dean O.M. Dowling N. Smith D.J. Murphy J. Menon R. Berk M. Blair-West S. Ng C.H. N-Acetyl Cysteine (NAC) in the treatment of obsessive-compulsive disorder: A 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs 2015 29 9 801 809 [http://dx.doi.org/10.1007/s40263-015-0272-9]. [PMID: 26374743]. 26374743 · DOI
  100. [124]Paydary K. Akamaloo A. Ahmadipour A. Pishgar F. Emamzadehfard S. Akhondzadeh S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J. Clin. Pharm. Ther. 2016 41 2 214 219 [http://dx.doi.org/10.1111/jcpt.12370]. [PMID: 26931055]. 26931055 · DOI
  101. [125]Costa D.L. Diniz J.B. Requena G. Joaquim M.A. Pittenger C. Bloch M.H. Miguel E.C. Shavitt R.G. Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. 2017 28617566
  102. [126]González J.C. Egea J. Del Carmen Godino M. Fernandez-Gomez F.J. Sánchez-Prieto J. Gandía L. García A.G. Jordán J. Hernández-Guijo J.M. Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca(2+) signalling in hippocampal neurons. Eur. J. Neurosci. 2007 26 9 2481 2495 [http://dx.doi.org/10.1111/j.1460-9568.2007.05873.x]. [PMID: 17986028]. 17986028 · DOI
  103. [127]Rodriguez C.I. Bender J. Jr Marcus S.M. Snape M. Rynn M. Simpson H.B. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. J. Clin. Psychiatry 2010 71 9 1247 1249 [http://dx.doi.org/10.4088/ JCP.09l05805blu]. [PMID: 20923629]. 20923629 PMC3923525
  104. [128]Esalatmanesh S. Abrishami Z. Zeinoddini A. Rahiminejad F. Sadeghi M. Najarzadegan M.R. Shalbafan M.R. Akhondzadeh S. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry Clin. Neurosci. 2016 70 11 517 526 [http://dx.doi.org/10.1111/pcn.12430]. [PMID: 27488081]. 27488081 · DOI
  105. [129]Walker D.L. Ressler K.J. Lu K.T. Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J. Neurosci. 2002 22 6 2343 2351 [PMID: 11896173]. 11896173 PMC6758267
  106. [130]Storch E.A. Merlo L.J. Bengtson M. Murphy T.K. Lewis M.H. Yang M.C. Jacob M.L. Larson M. Hirsh A. Fernandez M. Geffken G.R. Goodman W.K. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 2007 22 230 237 [http://dx.doi.org/10.1097/YIC.0b013e32819f8480]. 17519647 · DOI · Paper page
  107. [131]Kushner M.G. Kim S.W. Donahue C. Thuras P. Adson D. Kotlyar M. McCabe J. Peterson J. Foa E.B. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol. Psychiatry 2007 62 8 835 838 [http://dx.doi.org/10.1016/j.biopsych.2006.12.020]. [PMID: 17588545]. 17588545 · DOI
  108. [134]Andersson E. Hedman E. Enander J. Radu Djurfeldt D. Ljótsson B. Cervenka S. Isung J. Svanborg C. Mataix-Cols D. Kaldo V. Andersson G. Lindefors N. Rück C. d-Cycloserine vs placebo as adjunct to cognitive behavioural therapy for obsessive-compulsive disorder and interaction with antidepressants: a randomized clinical trial. JAMA Psychiatry 2015 72 7 659 667 [http://dx.doi.org/10.1001/jamapsychiatry.2015.0546]. [PMID: 25970252]. 25970252 · DOI
  109. [135]Bonanno G. Giambelli R. Raiteri L. Tiraboschi E. Zappettini S. Musazzi L. Raiteri M. Racagni G. Popoli M. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J. Neurosci. 2005 25 13 3270 3279 [http://dx.doi.org/10.1523/JNEUROSCI.5033-04.2005]. [PMID: 15800181]. 15800181 PMC6724889 · DOI
  110. [136]de Leeuw A.S. van Megen H.J. Kahn R.S. Westenberg H.G. d-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder. Eur. Psychiatry 2017 40 38 44 [http://dx.doi.org/10.1016/j.eurpsy.2016.06.011]. [PMID: 27837671]. 27837671 · DOI
  111. [137]Storch E.A. Murphy T.K. Goodman W.K. Geffken G.R. Lewin A.B. Henin A. Micco J.A. Sprich S. Wilhelm S. Bengtson M. Geller D.A. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol. Psychiatry 2010 68 11 1073 1076 [http://dx.doi.org/10.1016/j.biopsych.2010.07.015]. [PMID: 20817153]. 20817153 PMC3034091 · DOI
  112. [138]Farrell L.J. Waters A.M. Boschen M.J. Hattingh L. McConnell H. Milliner E.L. Collings N. Zimmer-Gembeck M. Shelton D. Ollendick T.H. Testa C. Storch E.A. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Depress. Anxiety 2013 30 8 723 731 [http://dx.doi.org/10.1002/da.22132]. [PMID: 23722990]. 23722990 · DOI
  113. [139]Mataix-Cols D. Turner C. Monzani B. Isomura K. Murphy C. Krebs G. Heyman I. Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. Br. J. Psychiatry 2014 204 1 77 78 [http://dx.doi.org/10.1192/bjp.bp.113. 126284]. [PMID: 24262813]. 24262813 · DOI
  114. [140]Park J.M. Small B.J. Geller D.A. Murphy T.K. Lewin A.B. Storch E.A. Does d-cycloserine augmentation of CBT improve therapeutic homework compliance for pediatric obsessive-compulsive disorder? J. Child Fam. Stud. 2014 23 5 863 871 [http://dx.doi.org/10.1007/s10826-013-9742-1]. [PMID: 24999301]. 24999301 PMC4078886 · DOI
  115. [141]Storch E.A. Wilhelm S. Sprich S. Henin A. Micco J. Small B.J. McGuire J. Mutch P.J. Lewin A.B. Murphy T.K. Geller D.A. Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine vs placebo in pediatric obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry 2016 73 8 779 788 [http://dx.doi.org/10.1001/jamapsychiatry. 2016.1128]. [PMID: 27367832]. 27367832 PMC5734635 · DOI
  116. [142]Oliver G. Dean O. Camfield D. Blair-West S. Ng C. Berk M. Sarris J. N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clin. Psychopharmacol. Neurosci. 2015 13 1 12 24 [http://dx.doi.org/10.9758/cpn.2015.13.1.12]. [PMID: 25912534]. 25912534 PMC4423164 · DOI · Paper page
  117. [143]Prabhavalkar K.S. Poovanpallil N.B. Bhatt L.K. Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer. Front. Pharmacol. 2015 6 242 [http://dx.doi.org/10.3389/ fphar.2015.00242]. [PMID: 26557090]. 26557090 PMC4615936
  118. [144]Pittenger C. Glutamatergic agents for OCD and related disorders. Curr. Treat. Options Psychiatry 2015 2 3 271 283 [http://dx.doi.org/10.1007/s40501-015-0051-8]. [PMID: 26301176]. 26301176 PMC4540409 · DOI · Paper page
  119. [145]Laoutidis Z.G. Lekka G.E. Kioulos K.T. Glutamatergic agents as add-on medication for the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis. J. Clin. Psychiatry 2016 77 12 e1576 e1583 [http://dx.doi.org/10.4088/JCP. 15r10164]. [PMID: 27780337]. 27780337 · DOI
  120. [146]Real E. Gratacòs M. Labad J. Alonso P. Escaramís G. Segalàs C. Subirà M. López-Solà C. Estivill X. Menchón J.M. Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive-compulsive disorder. Pharmacogenomics J. 2013 13 5 470 475 [http://dx.doi.org/10.1038/ tpj.2012.30]. [PMID: 22776887]. 22776887

Authors
Marinova, Z., Chuang, D.-M., & Fineberg, N.
Affiliations
  • Klinik Barmelweid (CH)
  • National Institutes of Health (US)
  • University of Hertfordshire (GB)
Corresponding author
Marinova, Zoya
ORCID
Fineberg, Naomi
Venue
Current Neuropharmacology
Publisher
Bentham Science Publishers Ltd.
Published
2017-08-28
Volume
15
Issue
7
Pages
977-995
ISSN
1570-159X (ISSN-L)
DOI
10.2174/1570159x15666170320104237
PMC
PMC5652017
OpenAlex
W2752397193
Cited by
83
References
154
Citations by year
2026: 8 · 2025: 7 · 2024: 6 · 2023: 10 · 2022: 11 · 2021: 18 · 2020: 3 · 2019: 8 · 2018: 11 · 2017: 1
FWCI
0.96
Type
journal article
Language
en
Open access
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
obsessive-compulsive disorder, glutamatergic signalling, memantine, lamotrigine, topiramate, riluzole, ketamine, augmentation therapy, treatment-resistant OCD, antiepileptic drugs
MeSH terms
Clinical Trials as Topic, Humans, Obsessive-Compulsive Disorder, Psychotropic Drugs, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review